Neil Bifulco - Department of Medicinal Chemistry, GlaxoSmithKline Research and Development

基本信息

Career Trajectory

Bio

No content for now

Research Interests

Papers共 39 篇Author StatisticsCo-AuthorSimilar Experts

By YearBy Citation主题筛选期刊级别筛选合作者筛选合作机构筛选

REX-7117 is a Highly Potent and Selective Oral STAT3 Inhibitor That Demonstrated Potential Efficacy and Safety Differentiation Versus JAK/TYK2 Targeting in Preclinical Models of Inflammatory Arthritis

Alexandra Gardino,Neil Bifulco, Jeremy Hunt, Rishi Vaswani, Donglim Park, Patrick Metz, Ksenya Cohen-Katsenelson, Jeong-Ho Kim, Xia Tian, Aryan Alavi, Ajay Nirula, Daniel Treiber,Brian Hodous, Seong Kim,Paul Smith

ARTHRITIS & RHEUMATOLOGY (2024): 1958-1959

Cited0Views0Bibtex

Abstract P6-10-07: CDK2 Inhibition with BLU-222 in Combination with Ribociclib Demonstrates Robust Antitumor Activity in Pre-Clinical Models of CDK4/6 Inhibitor-Naïve and -Resistant HR+/HER2- Breast Cancer

Victoria Brown,Nealia House,Phil Ramsden,Karen Ho,Hsin-Jung Wu,Erik Wilker, Jian Guo,Maxine Chen,Douglas Wilson,Neil Bifulco,Steve Wenglowsky,Yoon Jong Choi,Kerrie Faia

Cancer Researchno. 5_Supplement (2023): P6-10

Cited1Views0Bibtex

Supplementary Methods, Figure Legends from First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

Margit Hagel,Chandra Miduturu,Michael Sheets,Nooreen Rubin,Weifan Weng,Nicolas Stransky,Neil Bifulco,Joseph L. Kim,Brian Hodous,Natasja Brooijmans,Adam Shutes,Christopher Winter,Christoph Lengauer,Nancy E. Kohl,Timothy Guzi

openalex（2023）

Cited0Views0Bibtex

CDK2 Inhibition with BLU-222 in Combination with Ribociclib Demonstrates Robust Antitumor Activity in Pre-Clinical Models of CDK4/6 Inhibitor-Naive and -Resistant HR+/HER2-breast Cancer

Victoria Brown,Nealia House,Phil Ramsden,Karen Ho,Hsin-Jung Wu,Erik Wilker, Jian Guo,Maxine Chen,Douglas Wilson,Neil Bifulco,Steve Wenglowsky,Yoon Jong Choi,Kerrie Faia

CANCER RESEARCHno. 5 (2023)

Cited0Views0Bibtex

Data from First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

crossref（2023）

Cited0Views0Bibtex

Supplementary Figures S1 - S6, Tables S1 - S2 from First Selective Small Molecule Inhibitor of FGFR4 for the Treatment of Hepatocellular Carcinomas with an Activated FGFR4 Signaling Pathway

openalex（2023）

Cited0Views0Bibtex

BLU-222, an Investigational, Potent, and Selective CDK2 Inhibitor, Demonstrated Robust Antitumor Activity in CCNE1-amplified Ovarian Cancer Models

Victoria Brown,Phil Ramsden,Nealia House,Richard Vargas,Jian Guo,Ruduan Wang,Riadh Lobbardi,Maxine Chen,Douglas Wilson,Joseph Kim,Neil Bifulco,Michelle Maynard,Emanuele Perola,Dean Zhang,Steve Wenglowsky,Yoon Jong Choi

Cancer Researchno. 12_Supplement (2022): 2306-2306

Cited3Views0Bibtex

Development of a Selective CDK2-E Inhibitor in CCNE Driven Cancers

Yoon J. Choi,Steve Wenglowsky,Victoria Brown,Neil Bifulco, Yeon S. Choi,Jian Guo,Megan Hatlen,Joseph Kim, Tim LaBranche,Riadh Lobbardi,Emanuele Perola,Emily Rozsahegyi,Michelle Maynard,Phil Ramsden,Grace Silva,Faith Stevison,Richard Vargas,Ruduan Wang,Doug Wilson,Rich Woessner,Dean Zhang, Rob Meissner,Klaus Hoeflich,Marion Dorsch

Cancer Research（2021）

Cited3Views0Bibtex

Author Statistics

Co-Author

Co-Institution

D-Core

合作者
学生
导师

No result temporarily, you can search similar Scholar with the same research interest

Data Disclaimer

The page data are from open Internet sources, cooperative publishers and automatic analysis results through AI technology. We do not make any commitments and guarantees for the validity, accuracy, correctness, reliability, completeness and timeliness of the page data. If you have any questions, please contact us by email: report@aminer.cn